OBJECTIVE: Symptomatic infections of the central nervous system (CNS) with JC polyomavirus (JCV) usually occur as a result of immunocompromise and manifest as progressive multifocal leukoencephalopathy (PML) or granule cell neuronopathy (GCN). After immune reconstitution, some of these cases may show long-term persistence of JCV and delayed clinical improvement despite inflammation. METHODS: We followed 4 patients with multiple sclerosis, who developed natalizumab-associated PML or GCN with regard to JC viral load and JCV-specific T-cell responses in the CNS. All of them experienced immune reconstitution inflammatory syndrome (IRIS), but in 2 cases JCV persisted > 21 months after IRIS accompanied by delayed clinical improvement. RESULTS: Persistence of JCV was associated with a lack of JCV VP1-specific T-cell responses during immune reconstitution in 1 of the patients. Detailed analysis of the brain infiltrate in another patient with neuronal persistence of JCV revealed strong infiltration of CD8(+) T cells and clonal expansion of activated CD8(+) effector T cells with a CD4(dim) CD8(+) phenotype, both exhibiting exquisite specificity for conserved epitopes of JCV large T antigen. However, clearance of JCV was not efficient, because mutations in the major capsid protein VP1 caused reduced CD4(+) T-cell responses against the identified JCV variant and subsequently resulted in a decline of CD8(+) T-cell responses after IRIS. INTERPRETATION: Our findings suggest that efficient CD4(+) T-cell recognition of neurotropic JCV variants is crucial to support CD8(+) T cells in combating JCV infection of the CNS.
OBJECTIVE: Symptomatic infections of the central nervous system (CNS) with JC polyomavirus (JCV) usually occur as a result of immunocompromise and manifest as progressive multifocal leukoencephalopathy (PML) or granule cell neuronopathy (GCN). After immune reconstitution, some of these cases may show long-term persistence of JCV and delayed clinical improvement despite inflammation. METHODS: We followed 4 patients with multiple sclerosis, who developed natalizumab-associated PML or GCN with regard to JC viral load and JCV-specific T-cell responses in the CNS. All of them experienced immune reconstitution inflammatory syndrome (IRIS), but in 2 cases JCV persisted > 21 months after IRIS accompanied by delayed clinical improvement. RESULTS: Persistence of JCV was associated with a lack of JCV VP1-specific T-cell responses during immune reconstitution in 1 of the patients. Detailed analysis of the brain infiltrate in another patient with neuronal persistence of JCV revealed strong infiltration of CD8(+) T cells and clonal expansion of activated CD8(+) effector T cells with a CD4(dim) CD8(+) phenotype, both exhibiting exquisite specificity for conserved epitopes of JCV large T antigen. However, clearance of JCV was not efficient, because mutations in the major capsid protein VP1 caused reduced CD4(+) T-cell responses against the identified JCV variant and subsequently resulted in a decline of CD8(+) T-cell responses after IRIS. INTERPRETATION: Our findings suggest that efficient CD4(+) T-cell recognition of neurotropic JCV variants is crucial to support CD8(+) T cells in combating JCV infection of the CNS.
Authors: Aabha Oza; Michael P Rettig; Phil Powell; Kathryn O'Brien; David B Clifford; Julie Ritchey; Leah Gehrs; Julia Hollaway; Eugene Major; Todd A Fehniger; Christopher A Miller; Patrick Soon-Shiong; Amy Rock; John F DiPersio Journal: Blood Adv Date: 2020-06-09
Authors: Spyros Chalkias; Joshua M Gorham; Erica Mazaika; Michael Parfenov; Xin Dang; Steve DePalma; David McKean; Christine E Seidman; Jonathan G Seidman; Igor J Koralnik Journal: PLoS One Date: 2018-01-23 Impact factor: 3.240
Authors: Faiez Al Nimer; Ivan Jelcic; Christian Kempf; Tom Pieper; Herbert Budka; Mireia Sospedra; Roland Martin Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-12-08
Authors: Irene Cortese; Erin S Beck; Omar Al-Louzi; Joan Ohayon; Frances Andrada; Ikesinachi Osuorah; Jenifer Dwyer; B Jeanne Billioux; Nigar Dargah-Zada; Matthew K Schindler; Kyle Binder; Lauren Reoma; Gina Norato; Yoshimi Enose-Akahata; Bryan R Smith; Maria Chiara Monaco; Eugene O Major; Steven Jacobson; David Stroncek; Steven Highfill; Sandhya Panch; Daniel S Reich; John Barrett; Avindra Nath; Pawel Muranski Journal: Lancet Neurol Date: 2021-08 Impact factor: 59.935